Drug intelligence / Profile preview

LNO-A02

Development stage: Preclinical
Lead developer: Linno Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LNO-A02 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Linno Pharmaceuticals (also known as Lingnuo Pharmaceuticals) for the treatment of hematological malignancies, specifically B-cell malignancies. It consists of a monoclonal antibody targeting CD22 conjugated to a cytotoxic payload. CD22 is a cell surface glycoprotein primarily expressed on B-cells and is a validated target in B-cell non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The ADC is designed to deliver the cytotoxic agent directly to CD22-expressing malignant cells, minimizing systemic toxicity.

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on LNO-A02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNO-A02.

Explore the full profile